Literature DB >> 7968162

ras mutations and expression in head and neck squamous cell carcinomas.

W G Yarbrough1, C Shores, D L Witsell, M C Weissler, M E Fidler, T M Gilmer.   

Abstract

Mutational activation and overexpression of the family of ras proto-oncogenes have been associated with many human tumors. The role of mutations of H-ras, K-ras, and N-ras, as well as expression of the respective protein products (p21s) in normal mucosa, dysplastic mucosa, and squamous cell carcinomas (SCCs) of the head and neck has not been fully described. In our study, 51 tumors (40 paraffin embedded and 11 fresh frozen) were examined to determine if mutational activation of ras is an important molecular event in head and neck SCC. Analyses of codons 12, 13, and 61 of H-ras, K-ras, and N-ras revealed no mutations, suggesting that mutational activation of ras is not important in the majority of head and neck SCCs. Immunocytochemistry (ICC) was used to define the expression of H-ras, K-ras, and N-ras in normal mucosa, dysplastic mucosa, and SCC of the head and neck and to determine if expression of ras family members correlated with early or late events in the development of SCC. Expression of p21N-ras in nine samples of histologically normal head and neck mucosa revealed moderate staining in the basal proliferative layers with progressively less staining as cells matured. The most superficial layers of normal mucosa failed to express p21N-ras. A low level of p21H-ras was expressed in all layers of normal mucosa while K-ras was not expressed. ICC of SCC tumor sections revealed cytoplasmic expression of N-ras in nine of nine tumors, H-ras in five of nine tumors, and K-ras in one of nine tumors. Expression of H-ras, K-ras, and N-ras in head and neck SCC was not related to histologic differentiation or TNM staging; however, p21N-ras was overexpressed in seven of nine tumors. Furthermore, the pattern of N-ras expression in dysplastic lesions revealed expression in all layers of the mucosa in contrast to normal mucosa, which expresses p21N-ras primarily in the basal proliferative layer. The change in p21N-ras expression pattern in dysplastic mucosa and its overexpression in the majority of tumors suggest that loss of control of N-ras expression may be an early step in carcinogenesis of head and neck SCC.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7968162     DOI: 10.1288/00005537-199411000-00005

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  23 in total

1.  Expression of ets-1 is not affected by N-ras or H-ras during oral oncogenesis.

Authors:  Eleftherios Vairaktaris; Georgios Papageorgiou; Spyridoula Derka; Panagiota Moulavassili; Emeka Nkenke; Peter Kessler; Stavros Vassiliou; Veronica Papakosta; Sofia Spyridonidou; Antonis Vylliotis; Andreas C Lazaris; Sofia Anagnostopoulou; Constantinos Mourouzis; Christos Yapijakis; Efstratios Patsouris
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-28       Impact factor: 4.553

2.  Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples.

Authors:  Mitchell J Frederick; Amy J VanMeter; Mayur A Gadhikar; Ying C Henderson; Hui Yao; Curtis C Pickering; Michelle D Williams; Adel K El-Naggar; Vlad Sandulache; Emily Tarco; Jeffrey N Myers; Gary L Clayman; Lance A Liotta; Emanuel F Petricoin; Valerie S Calvert; Valentina Fodale; Jing Wang; Randal S Weber
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

3.  Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma.

Authors:  Karl C Bruckman; Frank Schönleben; Wanglong Qiu; Victoria L Woo; Gloria H Su
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2010-09-01

Review 4.  Molecular pathogenesis of head and neck squamous cell carcinoma.

Authors:  David Hardisson
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-05-08       Impact factor: 2.503

5.  Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.

Authors:  Christine H Chung; Erin H Seeley; Heinrich Roder; Julia Grigorieva; Maxim Tsypin; Joanna Roder; Barbara A Burtness; Athanassios Argiris; Arlene A Forastiere; Jill Gilbert; Barbara Murphy; Richard M Caprioli; David P Carbone; Ezra E W Cohen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01-19       Impact factor: 4.254

6.  PIK3CA mutations in head and neck squamous cell carcinoma.

Authors:  Wanglong Qiu; Frank Schönleben; Xiaojun Li; Daniel J Ho; Lanny G Close; Spiros Manolidis; Boyce P Bennett; Gloria H Su
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

7.  Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck.

Authors:  Francesco Perri; Francesco Longo; Franco Ionna; Francesco Caponigro
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

8.  Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.

Authors:  Nancy Van Damme; Philippe Deron; Nadine Van Roy; Pieter Demetter; Alain Bols; Jo Van Dorpe; Filip Baert; Jean-Luc Van Laethem; Franki Speleman; Patrick Pauwels; Marc Peeters
Journal:  BMC Cancer       Date:  2010-05-11       Impact factor: 4.430

9.  Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.

Authors:  L Licitra; R Mesia; F Rivera; É Remenár; R Hitt; J Erfán; S Rottey; A Kawecki; D Zabolotnyy; M Benasso; S Störkel; S Senger; C Stroh; J B Vermorken
Journal:  Ann Oncol       Date:  2010-11-03       Impact factor: 32.976

10.  Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway.

Authors:  A C Hoover; G L Strand; P N Nowicki; M E Anderson; P D Vermeer; A J Klingelhutz; A D Bossler; J V Pottala; W J A J Hendriks; J H Lee
Journal:  Oncogene       Date:  2009-09-07       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.